KROS Stock Forecast: Keros Therapeutics, Inc. Price Predictions for 2026-2027
The 7 Wall Street analysts covering Keros Therapeutics, Inc. hold a median 12-month price target of $19 — +71.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 83 of 100 as at 21 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Keros Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Issuance (96): The share count has been shrinking and the company is not leaning on new borrowing.
Growth (12): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
KROS stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on KROS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +71.5% from it.
Of the 20 most recent actions, 0 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 4 Aug 2026 | Leerink Partners | Maintains | Outperform | $30 → $23 |
| 4 Aug 2026 | Wells Fargo | Maintains | Overweight | $20 → $18 |
| 5 Mar 2026 | Wells Fargo | Maintains | Overweight | $23 → $20 |
| 28 Nov 2025 | B of A Securities | Maintains | Neutral | — |
| 12 Nov 2025 | Oppenheimer | Reiterates | Outperform | — |
| 11 Nov 2025 | Wells Fargo | Maintains | Overweight | — |
| 6 Nov 2025 | Wedbush | Maintains | Neutral | — |
| 8 Aug 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 10 June 2025 | B of A Securities | Downgrade | Neutral | — |
| 30 May 2025 | Wedbush | Reiterates | Neutral | — |
| 12 May 2025 | Scotiabank | Maintains | Sector Outperform | — |
| 8 May 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 9 Apr 2025 | Truist Securities | Maintains | Buy | — |
| 1 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 1 Apr 2025 | Wedbush | Reiterates | Neutral | — |
| 27 Feb 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 27 Feb 2025 | Wells Fargo | Maintains | Overweight | — |
| 21 Jan 2025 | Cantor Fitzgerald | Downgrade | Neutral | — |
| 17 Jan 2025 | Guggenheim | Reiterates | Neutral | — |
| 17 Jan 2025 | Piper Sandler | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for KROS.
This page is one stock. Monday covers all of them.
KROS appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
KROS vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Keros Therapeutics, Inc. returned −34.1% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
KROS analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 5.8×
- Price / book
- 0.9×
- EV / EBITDA
- —
Cheaper than 19% of US stocks
Cheaper than 76% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −12.6%
- Return on assets
- −8.4%
- Dividend yield
- —
Higher than 35% of US stocks
Higher than 28% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Keros Therapeutics, Inc. has a market value of $222.0M.
Revenue in the twelve months to 30 June 2026: $15.0M. The latest quarter shrank 100.0% year on year.
Net income over the same four quarters: −$83.2M, a −553.9% net margin.
Diluted earnings per share, trailing twelve months: −$3.70.
Free cash flow in the twelve months to 30 June 2026: −$48.5M.
Keros Therapeutics, Inc. employs 87 people — $173K of revenue per employee.
Data provided by Twelve Data
KROS and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at KROS’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Keros Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about KROS
What is the KROS stock price forecast for 2026-2027?
The 7 Wall Street analysts covering Keros Therapeutics, Inc. have a median 12-month price target of $19, with estimates ranging from $16 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is KROS stock a buy right now?
Of the 7 analysts covering Keros Therapeutics, Inc., 4 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Keros Therapeutics, Inc. 83 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank KROS?
As at 21 Nov 2026, Keros Therapeutics, Inc. ranks 83 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Issuance (96 of 100).
Will KROS stock go up?
No one can know that. What the data says: the median 12-month target from 7 analysts implies +71.5% from the last close, and Ticker Nerd's factor model ranks Keros Therapeutics, Inc. 83 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the KROS stock forecast for 2030?
No analyst covering Keros Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KROS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $16 to $25 over the next 12 months.
How has KROS stock performed over the past year?
Keros Therapeutics, Inc. returned -34.1% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Keros Therapeutics, Inc. do?
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for disorders linked to dysfunctional signaling in the transforming growth factor-beta family of proteins. Its current pipeline centers on candidates designed to address serious hematologic, pulmonary, cardiovascular, and musculoskeletal conditions, with research programs aimed at low blood cell counts, anemia, pulmonary arterial hypertension, bone-related disorders, and muscle-related diseases.
About Keros Therapeutics, Inc.
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for disorders linked to dysfunctional signaling in the transforming growth factor-beta family of proteins. Its current pipeline centers on candidates designed to address serious hematologic, pulmonary, cardiovascular, and musculoskeletal conditions, with research programs aimed at low blood cell counts, anemia, pulmonary arterial hypertension, bone-related disorders, and muscle-related diseases. The company’s work is built around protein- and pathway-based approaches that target disease mechanisms involved in red blood cell and platelet production, iron regulation, and tissue repair. Keros Therapeutics serves the biotechnology and specialty medicine markets, where it contributes to the development of precision therapies for patients with high unmet medical needs.
CEO Dr. Jasbir S. Seehra Ph.D. · 87 employees · United States · https://www.kerostx.com